Malaria is a major infectious disease in the world with tremendous impact on quality of life. Malaria control is difficult and the available tools are limited. Vaccines will be the only long-term and cost-effective tools to control this ever-growing problem. Malaria is transmitted by sexual stages of Plasmodium falciparum. Sexual stage malaria vaccines aim at an arrest of the transmission and therefore spread or (re)-introduction of malaria in a risk area. The objectives are focussed on production and development of a transmission-blocking (TB)-vaccine. The objectives and expected outcome include
1) production of a TBPfs48/45 peptide vaccine up to the phase of clinical testing
2) identification of novel parasite antigens on gametocyte-infected red blood cells, gametes/kookiness and mosquitoes.
3) improvement of (bio)-assays for TB-immunity by the use of quantitative molecular techniques and development of immune correlates of protection.
4) Application of (new) animal models (marine, non-human primates) to be used in studies on biological function with genetically modified parasites and for pre-screening for human trials.
Funding SchemeCSC - Cost-sharing contracts
2280 GH Rijswijk Zh
SW7 2AZ London
2311 EZ Leiden
1099 085 Lisboa
AB9 2TN Aberdeen